MY160699A - Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome - Google Patents

Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Info

Publication number
MY160699A
MY160699A MYPI2011000225A MYPI2011000225A MY160699A MY 160699 A MY160699 A MY 160699A MY PI2011000225 A MYPI2011000225 A MY PI2011000225A MY PI2011000225 A MYPI2011000225 A MY PI2011000225A MY 160699 A MY160699 A MY 160699A
Authority
MY
Malaysia
Prior art keywords
dengue
fever
infections
mediated
methods
Prior art date
Application number
MYPI2011000225A
Other languages
English (en)
Inventor
Neil M Bodie
Original Assignee
Trinity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity Therapeutics Inc filed Critical Trinity Therapeutics Inc
Publication of MY160699A publication Critical patent/MY160699A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI2011000225A 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome MY160699A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8194308P 2008-07-18 2008-07-18

Publications (1)

Publication Number Publication Date
MY160699A true MY160699A (en) 2017-03-15

Family

ID=41551029

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011000225A MY160699A (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Country Status (13)

Country Link
US (1) US8815813B2 (enExample)
EP (1) EP2320924B1 (enExample)
JP (1) JP5806112B2 (enExample)
CN (1) CN102159231B (enExample)
AU (2) AU2009270805B2 (enExample)
BR (1) BRPI0915968B1 (enExample)
CA (1) CA2731218A1 (enExample)
HR (1) HRP20150620T1 (enExample)
IL (1) IL210717A (enExample)
MX (1) MX2011000647A (enExample)
MY (1) MY160699A (enExample)
SG (1) SG10201500597YA (enExample)
WO (1) WO2010009380A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086947A2 (en) * 2004-03-10 2005-09-22 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
WO2010009380A2 (en) 2008-07-18 2010-01-21 Trinity Therapeutics, Inc. Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
EP3236986A4 (en) * 2014-12-22 2018-10-24 Middle Tennessee State University Methods for treating immune-mediated viral infections
SG11201709573YA (en) * 2015-05-20 2017-12-28 Univ Kagoshima Specific modification of antibody with igg-binding peptide
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
CN109071606A (zh) 2016-06-13 2018-12-21 国立大学法人鹿儿岛大学 利用IgG结合肽的位点特异性放射性同位素标记抗体
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4383317A (en) 1980-10-30 1983-05-10 Bei Electronics, Inc. Shaft angle encoder having a circuit for synthesizing a skipped track output signal
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5693758A (en) 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
ITMI962628A1 (it) 1996-12-16 1998-06-16 Tecnogen Scpa Composizione farmaceutica
WO2000015214A1 (en) 1998-09-11 2000-03-23 Ilexus Pty Limited Fc RECEPTOR MODULATORS AND USES THEREOF
DE69926009D1 (de) 1998-10-13 2005-08-04 Univ Georgia Res Found Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2002038592A2 (de) 2000-11-08 2002-05-16 Affina Immuntechnik Gmbh Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
JP2005528918A (ja) 2002-06-07 2005-09-29 アースロン・リミテッド 自己免疫疾患用のＦｃγＲＩＩａトランスジェニック動物モデル
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
WO2005086947A2 (en) 2004-03-10 2005-09-22 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
EP1789067B8 (en) 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
EP1940436B1 (en) 2005-09-06 2013-12-04 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases
EP1960427B1 (en) 2005-12-13 2011-02-23 SuppreMol GmbH Multimeric fc receptor polypeptides
US20120021988A1 (en) 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
WO2010009380A2 (en) 2008-07-18 2010-01-21 Trinity Therapeutics, Inc. Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Also Published As

Publication number Publication date
EP2320924B1 (en) 2015-03-11
CN102159231B (zh) 2016-06-15
CN102159231A (zh) 2011-08-17
AU2009270805B2 (en) 2016-11-03
SG10201500597YA (en) 2015-04-29
US20110218157A1 (en) 2011-09-08
JP5806112B2 (ja) 2015-11-10
EP2320924A4 (en) 2012-07-25
AU2009270805A1 (en) 2010-01-21
MX2011000647A (es) 2011-09-29
BRPI0915968B1 (pt) 2021-11-23
EP2320924A1 (en) 2011-05-18
BRPI0915968A2 (pt) 2020-08-18
JP2011528665A (ja) 2011-11-24
US8815813B2 (en) 2014-08-26
WO2010009380A2 (en) 2010-01-21
HRP20150620T1 (xx) 2015-09-25
IL210717A (en) 2017-07-31
IL210717A0 (en) 2011-03-31
AU2017200760A1 (en) 2017-03-02
CA2731218A1 (en) 2010-01-21
HK1158066A1 (en) 2012-07-13
WO2010009380A9 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
MY160699A (en) Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
NZ616254A (en) Complexes of il-15 and il-15ralpha and uses thereof
EP4292659A3 (en) Antibodies that neutralize hepatitis b virus and uses thereof
CR20200467A (es) Agentes anticuerpos anti-cd25
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
EA202092417A1 (ru) Химерные рецепторы к dll3 и способы их применения
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
WO2009117030A3 (en) Improved compositions for the prevention and treatment of smallpox
FR2919804B1 (fr) Composition et vaccin therapeutique anti-tumoral
TR201815254T4 (tr) Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari
MX343879B (es) Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
PH12022550056A1 (en) Dll3-targeting antibodies and uses thereof
JP2013166763A5 (enExample)
NZ720765A (en) Antibodies and methods of use
WO2008103849A3 (en) Methods and compounds for lymphoma cell detection and isolation
MX2019001767A (es) Anticuerpos monoclonales que se unen al dominio de union a lipidos de la proteina de la capside del virus de la hepatitis c (vhc).
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
WO2013142300A3 (en) Jcv neutralizing antibodies
Tsouchnikas et al. Immunization with immune complexes modulates the fine specificity of antibody responses to a flavivirus antigen
DE60140972D1 (de) Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen
CR20230025A (es) Muteínas de il-10 y proteínas de fusión de las mismas referencia cruzada a solicitudes relacionadas
JP2007513976A5 (enExample)
WO2016054053A3 (en) Hiv-1 antibodies and uses thereof (adcc and bispecific abs)